Chinar Therapeutics

Chinar Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative therapies for rare genetic disorders and neurodegenerative diseases. The company's primary focus is on targeting the glucocerebrosidase (GBA) pathway, which is implicated in Gaucher disease and GBA-associated Parkinson's disease. Their lead program, CT-101, is a brain-penetrant small molecule designed to restore enzyme function and reduce toxic substrate accumulation. By leveraging deep expertise in lysosomal biology, Chinar aims to address significant unmet medical needs in patient populations with limited treatment options. The company is led by an experienced management team with a proven track record in the successful development and commercialization of orphan drugs.